Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen

Drug Metabolism and Disposition

Volumn 30, Issue 5, 2002, Pages 608-612

  Desai, Pankaj B ^a,b   Nallani, Srikanth C ^a,b   Sane, Rucha S ^a,b   Moore, Linda B ^c   Goodwin, Bryan J ^c   Buckley, Donna J ^a,b   Buckley, Arthur R ^a,b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; CYTOCHROME P450 3A4; DRUG METABOLITE; DRUG METABOLIZING ENZYME; MESSENGER RNA; PREGNANE X RECEPTOR; RIFAMPICIN; TAMOXIFEN; TESTOSTERONE;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYDROXYLATION; IMMUNOREACTIVITY; LIVER CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; HEPATOCYTES; HUMANS; MIXED FUNCTION OXYGENASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RNA, MESSENGER; TAMOXIFEN;

EID: 0036239630     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.5.608     Document Type: Article

References (24)

1. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: A sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial
2. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction
3. SXR, a novel steroid and xenobiotic-sensing nuclear receptor
4. Genomic sequencing
5. Cellular and molecular pharmacology of antiestrogen action and resistance
6. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes
7. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer
8. Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen
9. Tamoxifen metabolism: Pharmacokinetic and in vitro study
10. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module
11. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer
12. The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution
13. Induction of cytochrome P4503A by laxol in primary cultures of human hepatocytes
14. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions
15. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment
16. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment
17. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor
18. Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: Comparative evaluation with paclitaxel
19. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes
20. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia
21. Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver
22. Induction of CYP2B1 and 3A 1, and associated monooxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice
23. CYP3A
24. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR